DCN Dx has received a growth equity investment from Martis Capital
DCN Dx, a leading provider of contract development services, has received a growth equity investment from Martis Capital.
DCN Dx offers contract development services for clients seeking to explore, develop and commercialize rapid diagnostic tests related to lateral flow assay. DCN Dx supports an array of customers including global diagnostics manufacturers, nonprofits seeking tests for low-resource settings and start-ups launching diagnostic-based products. Over the past 15 years, DCN Dx has successfully developed more than 100 rapid diagnostic tests for its customers.
Martis Capital is a private equity firm which manages more than US$1.2 billion of equity and is focused exclusively on investing in middle-market growth companies in the healthcare industry.
One of Oaklins’ teams in the USA, together with Pegasus Capital, served as a financial advisor to DCN Dx, in connection with a growth equity investment from Martis Capital.
Talk to the deal team
Bradford A. Adams
Oaklins TM Capital
Michael S. Goldman
Oaklins TM Capital
James McLaren
Oaklins TM Capital
Related deals
iwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets
iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.
Learn moreChequers Capital has acquired Gourmet Italian Food to strengthen presence in the ready meals sector
Chequers Partenaires S.A., acting as the management company of the private equity fund Chequers Capital XVIII SLP, together with management, has completed the acquisition of 100% of the share capital of Gourmet Italian Food S.p.A. (GIF). The company was previously owned by Alcedo SGR S.p.A. through the Alcedo IV Fund, FVS SGR S.p.A. through the Sviluppo PMI Fund, and minority shareholders.
Learn morePharma-Skan & Skan-Medic have been acquired by Brygge Partners
Pharma-Skan, an independent contract manufacturing organization (CMO), and Skan-Medic, a manufacturer of over-the-counter (OTC) products, both operating as a joint entity, have been acquired by Brygge Partners.
Learn more